Aspire Biopharma Reschedules Shareholder Meeting Due to Lack of Quorum

Aspire Biopharma Holdings, Inc. filed a Form 8-K reporting that its shareholder meeting, originally scheduled for June 9, 2026, was adjourned due to the lack of a quorum. A quorum is necessary for the company to conduct official business and vote on proposed matters. Consequently, the meeting has been rescheduled to June 16, 2026, at 10:00 a.m. EST. Shareholders can access the adjourned meeting via the same virtual link previously provided (www.colonialstock.com/AspireBiopharma2026). The filing was signed by Kraig T. Higginson, the company's Chief Executive Officer and Chairman, on June 12, 2026. This administrative delay does not reflect on the company's clinical pipeline or financial health but pertains strictly to corporate governance and shareholder participation requirements. No other material events or changes to the meeting's agenda were disclosed in this report.